368 related articles for article (PubMed ID: 10416590)
21. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
[TBL] [Abstract][Full Text] [Related]
22. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
23. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells.
Stoitzner P; Green LK; Jung JY; Price KM; Atarea H; Kivell B; Ronchese F
Cancer Immunol Immunother; 2008 Nov; 57(11):1665-73. PubMed ID: 18311487
[TBL] [Abstract][Full Text] [Related]
24. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients.
Verdijk P; Aarntzen EH; Lesterhuis WJ; Boullart AC; Kok E; van Rossum MM; Strijk S; Eijckeler F; Bonenkamp JJ; Jacobs JF; Blokx W; Vankrieken JH; Joosten I; Boerman OC; Oyen WJ; Adema G; Punt CJ; Figdor CG; de Vries IJ
Clin Cancer Res; 2009 Apr; 15(7):2531-40. PubMed ID: 19318472
[TBL] [Abstract][Full Text] [Related]
25. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
26. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
27. Truncated TERT mRNA transfected dendritic cells evoke TERT specific antitumor response in vivo.
Qiu J; Lil GW; Sui YF; Sun YJ; Huang YY; Si SY; Ge W; Song HP
Hepatogastroenterology; 2007; 54(75):681-7. PubMed ID: 17591041
[TBL] [Abstract][Full Text] [Related]
28. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
[TBL] [Abstract][Full Text] [Related]
29. Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice.
Ribas A; Butterfield LH; Hu B; Dissette VB; Meng WS; Koh A; Andrews KJ; Lee M; Amar SN; Glaspy JA; McBride WH; Economou JS
Cancer Res; 2000 Apr; 60(8):2218-24. PubMed ID: 10786687
[TBL] [Abstract][Full Text] [Related]
30. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.
Okada H; Tsugawa T; Sato H; Kuwashima N; Gambotto A; Okada K; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Chambers WH; Potter DM; Storkus WJ; Pollack IF
Cancer Res; 2004 Aug; 64(16):5830-8. PubMed ID: 15313927
[TBL] [Abstract][Full Text] [Related]
31. Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects.
Moyer JS; Maine G; Mulé JJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1010-9. PubMed ID: 17084367
[TBL] [Abstract][Full Text] [Related]
32. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
33. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response.
Ji Q; Gondek D; Hurwitz AA
J Immunol; 2005 Aug; 175(3):1456-63. PubMed ID: 16034082
[TBL] [Abstract][Full Text] [Related]
34. Autoimmune depigmentation following sensitization to melanoma antigens.
Hurwitz AA; Ji Q
Methods Mol Med; 2004; 102():421-7. PubMed ID: 15286398
[TBL] [Abstract][Full Text] [Related]
35. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
36. Engineering of highly immunogenic long-lived DC vaccines by antiapoptotic protein gene transfer to enhance cancer vaccine potency.
Yoshikawa T; Niwa T; Mizuguchi H; Okada N; Nakagawa S
Gene Ther; 2008 Oct; 15(19):1321-9. PubMed ID: 18480845
[TBL] [Abstract][Full Text] [Related]
37. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity.
Wang TL; Ling M; Shih IM; Pham T; Pai SI; Lu Z; Kurman RJ; Pardoll DM; Wu TC
Gene Ther; 2000 May; 7(9):726-33. PubMed ID: 10822298
[TBL] [Abstract][Full Text] [Related]
38. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction.
Okada N; Mori N; Koretomo R; Okada Y; Nakayama T; Yoshie O; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A
Gene Ther; 2005 Jan; 12(2):129-39. PubMed ID: 15483669
[TBL] [Abstract][Full Text] [Related]
39. Efficient nonviral transfection of dendritic cells and their use for in vivo immunization.
Irvine AS; Trinder PK; Laughton DL; Ketteringham H; McDermott RH; Reid SC; Haines AM; Amir A; Husain R; Doshi R; Young LS; Mountain A
Nat Biotechnol; 2000 Dec; 18(12):1273-8. PubMed ID: 11101806
[TBL] [Abstract][Full Text] [Related]
40. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]